BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Integrated Biopharma Inc. INBP
15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$54.4M
▲ 8.0% vs FY2023
EPS · FY24
$0.03
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
4.1%
Net margin · FY24
1.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 54.4M
Revenue, FY2024 · full 15-year series below
Revenue
Net income
1 cents of every revenue dollar became profit this year.
Per share
USD 0.03
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
4.1%
Return on equity, FY2024
ROE
Operating margin3.7%
Net margin1.5%
Return on assets3.2%
Each USD of equity produced 4 cents of profit this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+0.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.1%
+0.6%
+3.8%
Net income
−40.5%
−27.8%
+1.0%
EPS, diluted
−37.0%
−25.4%
+4.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2024
Change, 5 years+4.8%
Change, 10 years+47.2%
The share count grew 5% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 24.9M
total assets, end of FY2024
Total assetsUSD 24.9M
EquityUSD 20.3M
CashUSD 3.6M
Current ratio4.42×
Equity funds 82% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
EBITDA $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
EPS, diluted $
0.03
0.00
0.00
0.12
0.25
0.13
0.06
0.02
0.10
0.05
0.02
0.01
0.00
−0.13
−0.11
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
4.1
0.6
−0.2
23.3
78.6
103.2
·
·
·
·
·
·
·
·
·
Shares out B
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed